

THE IMPACT OF COVID-19 ON PATIENTS WITH ASTHMA

José Luis Izquierdo ^(1,2), Carlos Almonacid ^(2,3), Yolanda González ⁽⁴⁾, Carlos Del Rio-Bermúdez ⁽⁴⁾, Julio Ancochea ^(5,6,7), Remedios Cárdenas ⁽⁸⁾, and Joan B Soriano ^(5,6,7)

¹ Respiratory Medicine. University Hospital of Guadalajara, Guadalajara

² Department of Medicine and Medical Specialties. University of Alcalá, Madrid

³ Respiratory Medicine. University Hospital Ramón y Cajal, Madrid

⁴ Savana Medica

⁵ Respiratory Medicine. Hospital Universitario de La Princesa, Madrid

⁶ Universidad Autónoma de Madrid. Madrid

⁷ Respiratory Diseases Networking Biomedical Research Centre (CIBERES). Institute of Health Carlos III (ISCIII), Madrid

⁸ Allergy. University Hospital of Guadalajara, Guadalajara

All in Spain

Address for correspondence:

Dr. Joan B Soriano

Servicio de Neumología

Hospital Universitario de la Princesa-UAM

Diego de León 62, 28005-Madrid, Spain

Email: jbsoriano2@gmail.com

Cellular: +34 618867769

Funding. Grant COVID-19 UAH 2019/00003/016/001/005 from the University of Alcalá (Spain).

29 ABSTRACT

30 **Background:** From the onset of the COVID-19 pandemic, an association between the
31 severity of COVID-19 and the presence of certain medical chronic conditions has been
32 suggested. However, unlike influenza and other viruses, the burden of the disease in
33 patients with asthma has been less evident.

34 **Objective:** This study aims at a better understanding of the burden of COVID-19 in
35 patients with asthma and the impact of asthma, its related comorbidities, and treatment
36 on the prognosis of COVID-19.

37 **Methods:** We analyzed clinical data from patients with asthma from January 1st to May
38 10th, 2020 using big data analytics and artificial intelligence through the SAVANA
39 *Managei*[®] clinical platform.

40 **Results:** Out of 71,192 patients with asthma, 1,006 (1.41%) suffered from COVID-19.
41 Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-
42 19 were significantly older (55 vs. 42 years), predominantly female (66% vs. 59%), had
43 higher prevalence of hypertension, dyslipidemias, diabetes, and obesity, and smoked
44 more frequently. Contrarily, allergy-related factors such as rhinitis and eczema were less
45 frequent in asthmatic patients with COVID-19 ($P < .001$). Higher prevalence of
46 hypertension, dyslipidemia, diabetes, and obesity was also confirmed in those patients
47 with asthma and COVID-19 who required hospital admission. The percentage of
48 individuals using inhaled corticosteroids (ICS) was lower in patients who required
49 hospitalization due to COVID-19, as compared to non-hospitalized patients (48.3% vs.
50 61.5%; OR: 0.58: 95% CI 0.44 - 0.77). During the study period, 865 (1.21%) patients with
51 asthma were being treated with biologics. Although these patients showed increased
52 severity and more comorbidities at the ear, nose, and throat (ENT) level, their hospital
53 admission rates due to COVID-19 were relatively low (0.23%). COVID-19 increased
54 inpatient mortality in asthmatic patients (2.29% vs 0.54%; OR 2.29: 95% CI 4.35 – 6.66).

55 **Conclusion:** Our results indicate that the number of COVID-19 cases in patients with
56 asthma has been low, although higher than the observed in the general population.
57 Patients with asthma and COVID-19 were older and were at increased risk due to
58 comorbidity-related factors. ICS and biologics are generally safe and may be associated
59 with a protective effect against severe COVID-19 infection.

60 INTRODUCTION

61 Asthma remains a global major challenge for public health. Affecting approximately 272
62 million people of all ages (4.5% of adults aged 18-50), asthma is one of the most common
63 chronic disorders worldwide (1,2). In the United States, it has been estimated that up to
64 12 million people experience an acute exacerbation of their asthma ever year, a quarter
65 of which require hospitalization (3). In Europe, asthma ranks 14th in terms of duration and
66 associated disability, and leads to an estimated cost of EUR 25 billion per year (4). In
67 Spain, 5% of adults and 10% of children have asthma. However, up to 50% of patients
68 remain undiagnosed. Indeed, 8.6% of adults (aged 18-70) and 14% of children show
69 asthma-related symptoms, being dyspnea and cough the most common (4,5). Yet,
70 between 60% and 70% of patients with asthma in Spain are not properly controlled (6,
71 7). This is critical since patients with uncontrolled asthma may generate ten times as
72 much direct and indirect costs than controlled patients (1).

73 The severity of the disease is related to uncontrolled bronchial asthma in many
74 patients; in other cases, worsening symptoms and asthma exacerbation are associated
75 with treatment-related variables (e.g., inappropriate treatment, lack of adherence) or with
76 the presence of underlying risk factors (6-8), most notably viral respiratory infection.
77 Asthma exacerbations caused by respiratory infections or other conditions have a
78 negative impact on the patient's health status and lead to worse prognosis.

79 COVID-19 is the disease caused by the severe acute respiratory syndrome
80 coronavirus 2 (SARS-CoV-2). Clinically, the severity of COVID-19 can vary from mild to
81 very severe, causing mortality in some patients (9,10). The ongoing COVID-19 pandemic
82 certainly represents a major challenge for health systems globally. Since the beginning
83 of the pandemic, an association between COVID-19 severity and chronic medical
84 conditions such as cardiovascular disease, diabetes mellitus, and high blood pressure
85 has been suggested. Unlike influenza and other seasonal viruses however, the impact
86 of COVID-19 in patients with asthma has been less evident (11-14). On the other hand,

87 the severity and mortality of COVID-19 has been strongly related with age. Although the
88 virus can infect individuals of all ages, most severe cases to date have been described
89 in adults 55 years and older, and in patients with the aforementioned comorbidities. In
90 this age group, patients typically have more than one chronic condition, particularly
91 endocrine-metabolic and cardiovascular diseases. With this background, it is imperative
92 to characterize the clinical course of SARS-CoV-2 infection in patients with asthma and
93 assess the impact of asthma and asthma-related comorbidities and treatment in COVID-
94 19-related outcomes.

95 Emerging and rapidly evolving diseases such as COVID-19 are best understood
96 using population-based registries containing real-world information (15). In this context,
97 combining real-world data with big data analytics has the potential to increase our
98 understanding of the effects of COVID-19 in patients with asthma and identify new
99 strategies and management options for therapeutic intervention. A relevant data source
100 with the above-mentioned characteristics is the clinical information contained in patients'
101 electronic health records (EHR).

102 Using the clinical information captured in the EHRs of patients with asthma and
103 COVID-19, here we aimed to a) describe the frequency and clinical characteristics of
104 these patients and b) understand the clinical impact of COVID-19 on the clinical course
105 of patients with asthma. To achieve the study objectives, we used big data analytics and
106 artificial intelligence (AI) through the SAVANA *Manager*[®] clinical platform (16-17).

107

108 **METHODS**

109 This was a multi-center, non-interventional, retrospective study using free-text data
110 captured in the EHRs of patients diagnosed of COVID-19. The study period was January
111 1, 2019 - May 10, 2020.

112 We followed the Strengthening the Reporting of Observational Studies in
113 Epidemiology (STROBE) guidelines for reporting observational studies (18). The study
114 was conducted in accordance with legal and regulatory requirements and followed
115 research practices described in the ICH Guidelines for Good Clinical Practice, the
116 Declaration of Helsinki in its latest edition, the Guidelines for Good
117 Pharmacoepidemiology Practice (GPP), and local regulations. Given the retrospective
118 and observational nature of the study, physicians' prescribing habits and patient
119 assignment to a specific therapeutic strategy were solely determined by the physician,
120 team, or hospital concerned. Likewise, a standard informed consent does not apply to
121 this study. All actions towards data protection were taken in accordance with the
122 European Data Protection authorities' code of good practice regarding big data projects
123 and the European General Data Protection Regulation (GDPR). This study was
124 approved by the Ethics and Research Committee of the University Hospital of
125 Guadalajara (Spain).

126 Clinical data from a total of 2,034,921 patients with available EHRs in the region
127 of Castilla La-Mancha (Spain) were explored. Data were collected from all available
128 services, including inpatient and outpatient departments, emergency room, and primary
129 care.

130 The information from EHRs was extracted with Natural Language Processing
131 (NLP) and AI techniques using SAVANA *Manager*[®], a powerful multilingual (natural
132 language) engine for the analysis of free-text clinical information. This software is able
133 to interpret any content included in electronic clinical records, regardless of the electronic
134 system in which it operates. Importantly, this tool can capture numerical values and
135 clinical notes and transform them into accessible variables, thus allowing for the reuse
136 of the information captured in large-scale collections of clinical records (i.e., big data).
137 The data extraction process has four distinct phases aimed at transferring and
138 aggregating the data into the study database, namely a) Acquisition: data acquisition is

139 the responsibility of the participating site, in close collaboration with SAVANA's
140 Information Technology staff. In compliance with the EU GDPR, data were anonymized
141 and transferred to SAVANA during this phase; *b*) Integration: In this phase, data were
142 integrated into the database; *c*) NLP processing: SAVANA's *EHRead*[®] technology
143 applied NLP techniques to analyze and extract the unstructured free-text information
144 written in large amounts of EHRs. The NLP output is a synthetic patient database, as the
145 software creates a patient database from scratch. This process ensures that this
146 information is inaccessible and makes traceability to individual patients impossible; and
147 *d*) Validation, consisting of a medical validation of the tool's output by doctors and
148 researchers.

149 The terminology used by SAVANA is based on multiple sources such as
150 SNOMED CT (19), which includes medical codes, concepts, synonyms, and definitions
151 regarding symptoms, diagnoses, body structures, and substances commonly used in
152 clinical documentation. Due to the novel methodological approach of this study, we
153 complemented our clinical findings with the assessment of *EHRead's* performance. This
154 evaluation was aimed at verifying the system's accuracy in identifying records that
155 contain mentions of asthma and COVID-19 and its related variables. For a
156 comprehensive description of the evaluation procedure, see (19). Briefly, the annotations
157 made by the medical experts were used to generate the gold standard to assess the
158 performance of *EHRead's* output; performance is calculated in terms of the standard
159 metrics of accuracy (P), recall (R), and their harmonic mean F-score (20).

160 All statistical analyses were conducted using SPSS software (V25.0). Unless
161 otherwise indicated, qualitative variables are expressed as absolute frequencies and
162 percentages, while quantitative variables are expressed as means and standard
163 deviations. For the assessment of statistical significance of numerical variables, we used
164 independent samples Student's T-tests or ANOVA. To measure the relative distribution

165 of patients assigned to different categories of qualitative variables, we used Chi² tests.
166 In all cases, a p value for statistical significance was set at 0.05.

167

168 **RESULTS**

169 We identified 71,192 patients with asthma during the study period (January 1, 2019 -
170 May 10, 2020). The search terms used to identify patients with bronchial asthma are
171 listed in **eTable 1**. For the linguistic evaluation of the variable 'asthma', we obtained
172 Precision, Recall, and F- Scores of 0.88, 0.75, and 0.81, respectively; these metrics
173 indicate that patients with asthma were properly identified within the target population.
174 The patient flowchart for asthmatics with and without COVID-19 is depicted in **Figure 1**.

175 Patients' age (mean \pm SD) was 42 \pm 20 years; 59% of patients were women.
176 Overall, 1,006 (1.41%) asthma patients were also diagnosed with COVID-19. *EHRead*
177 identified COVID-19 with a Precision of 0,99, a Recall of 0,75, and a F-Score of 0,93;
178 again, these results indicate that within our population with asthma, COVID-19 cases
179 were accurately identified. COVID-19 diagnosis was confirmed by PCR in 61% of
180 patients (n = 611); in the remaining cases, and considering the epidemiological context
181 of the pandemic in the study area between March and May 2020, diagnosis was based
182 on rapid serological tests or clinical, radiological, and/or analytical evaluation, Notably,
183 the percentage (95% CI) of patients diagnosed with COVID-19 in the population of
184 patients with asthma (1.41%; 1.33 – 1.50) was significantly higher than in the general
185 population of Castilla La-Mancha (Spain) (0.86%; 0.85 – 0.87), $P < .001$.

186 Patients with asthma who also had a diagnosis of COVID-19 were older,
187 predominantly women, and had higher prevalence rates of hypertension, dyslipidemia,
188 diabetes, obesity, and smoking habits than asthmatic individuals without COVID-19 (all
189 $P < .05$). By contrast, atopy-related factors such as rhinitis or eczema were significantly
190 more frequent in patients without COVID-19 (**Table 1**). The higher prevalence of

191 hypertension, dyslipidemia, diabetes, and obesity was further confirmed in those patients
192 requiring hospital admission, as compared with those who only required outpatient
193 management (**Table 2**).

194 The proportion of patients with asthma using inhaled corticosteroids (ICS) was
195 significantly lower in individuals requiring hospital admission (48.3% vs 61.5%)
196 respectively, with an OR (95% CI) of 0.58 (0.44 - 0.77). The most common diagnosis in
197 hospitalized patients was pneumonia (91% of patients; n = 239), with great variability of
198 radiological expression. Different diagnoses associated with respiratory failure but with
199 normal lung radiology (data not shown) were found in 9% (n = 24) of patients.

200 Regardless of previous ICS or bronchodilator use, a total of 865 patients in the
201 study population were being treated with biologics during the study period, due to
202 previous poor control of the disease (**Table 3**). Biologics-treated patients showed a high
203 frequency of rhinitis and polyposis (50% in both cases), and a greater number of
204 bronchospasm episodes before treatment onset with biologics. Despite increased
205 severity and comorbidity of symptoms at the ear, nose, and throat (ENT) level, the need
206 for COVID-19-related hospital admission in biologics-treated patients with asthma was
207 relatively marginal (0.23%; 0.03 – 0.83). This proportion markedly differs from the
208 observed in both the general population and in the population of patients with asthma
209 not being treated with biologics; in both cases 26% of patients required hospitalization
210 due to COVID-19. Only one patient undergoing treatment with biologics died; he was a
211 52-year-old male with high blood pressure, diabetes mellitus, and dyslipidemia.

212 Compared with information from patients with asthma available since January
213 2019, the data collected during the study period (January 1st to May 10th, 2020) show
214 that COVID-19 significantly increased in-hospital mortality in this population (0.54% vs
215 2.29%), with an associated OR (95% CI) of 4.35 (2.84 - 6.66). For both periods, in-
216 hospital mortality mainly affected elderly patients, with an average age (\pm SD) of 76 (\pm 12)
217 years in patients with both asthma and COVID-19, and 78 (\pm 17) in COVID-19-free

218 patients with asthma, $P < .001$); most of these patients were women in both study periods
219 (61% and 71%, respectively, and had previously diagnosed comorbidities (**Table 4**). On
220 the other hand, the age distribution (mean \pm SD) of patients without asthma who died
221 from COVID-19 was 79 ± 11 years, and 63% ($n = 296$) of them were male.

222

223 **DISCUSSION**

224 The WHO declared the COVID-19 outbreak a global pandemic on March 11, 2020. Ever
225 since, clinicians worldwide have been particularly concerned about the impact of
226 patients' preexisting chronic conditions (particularly lung and cardiovascular diseases)
227 on the course of this new disease. Whereas high blood pressure and diabetes have been
228 closely associated with increased frequency of cases and severity of COVID-19, care-
229 related data suggest that COVID-19 has not affected patients with asthma to nearly the
230 same extent (13,21-23).

231 To shed light on this question, we have applied big data analytics and AI to
232 analyze the clinical information of a large cohort of patients with asthma and COVID-19.
233 Big data applications in healthcare (specifically the use of new technologies to manage
234 and extract the complex data generated in large volumes of EHRs) is an inescapable
235 reality (24). Crucially, most of the information contained in EHRs is found in an
236 unstructured form (e.g., as free-text narratives or clinical notes). The use of big data
237 analytics and cutting-edge methods in the realm of AI (i.e., NLP, machine learning) now
238 allows for the extraction and analysis of this valuable information in real time. The
239 software use in the present study enable the rapid evaluation of the main indicators of
240 various clinical processes while avoiding the selection biases that occur in audit or case
241 series studies, where only specialized centers and medical professionals participate in
242 the study. Importantly, the Spanish Autonomous Community of Castilla-La Mancha has
243 different features that optimize the use of this technology to analyze the clinical impact
244 of COVID-19 on patients with asthma. First, this region has been one of the most affected

245 by the pandemic in Spain, which in turn has been one of the most hard-hit countries in
246 Europe. Second, it has a good EHR system, which has been standardized and is shared
247 across all five provinces. Finally, the *SAVANA Manager*[®] tool is widely available in the
248 region, allowing access to large amounts of clinical information (25).

249 In the present study, we analyzed clinical data from the largest population of
250 asthma patients published to date ($n = 71,192$); 1,006 of these patients were diagnosed
251 with COVID-19. The study period was January 1, 2019-May 10, 2020. Although the
252 system allows us to analyze data from 2011 onwards, we selected this temporal cut-off
253 to include asthmatic patients with updated follow-up information and with the active form
254 of the disease.

255 The proportion of patients with both asthma and COVID-19 during the study
256 period was 1.41%, which is markedly higher than the 0.86% observed in the general
257 population. Although these data show a higher frequency of COVID-19 in patients with
258 asthma, the manifestation of the disease in this clinical population was not particularly
259 severe, with low rate of hospital admissions. In addition, this proportion is lower than the
260 reported for patients with other chronic diseases. Some of the reasons that may explain
261 this phenomenon include remission of seasonal influenza, lack of exposure to
262 environmental factors, greater monitoring of hygiene measures during lockdown in these
263 patients, the significant reduction in air pollution during this period, and/or better control
264 of the disease by improving adherence to treatment due to fear of worsening
265 symptomatology. This trend was already observed since the initial phases of the
266 pandemic in patient populations with other respiratory diseases such as COPD (26).

267 Comorbidities play a major role in the manifestation of COVID-19-related
268 complications. In our study, the manifestation of COVID-19 in patients with asthma was
269 favored by older age, male sex, and the presence of several comorbidities. High blood
270 pressure, dyslipidemia, diabetes, and obesity were the main risk factors for hospital
271 admission due to poor prognosis. The lower risk associated with rhinitis and eczema is

272 consistent with previous observations that allergic sensitization in asthma is linked to
273 lower expression of ACE2 receptors in both upper and lower respiratory airways,
274 suggesting a potential protective effect (27). As previously observed in the general
275 population, mortality due to COVID-19 in patients with asthma mainly occurred in the
276 elderly.

277 The possibility that different therapeutic options in patients with chronic
278 respiratory diseases affects the incidence and prognosis of COVID-19 has been a matter
279 of intense debate. As for asthma, it has been suggested that the use of ICS might yield
280 a protective effect against COVID-19 (28,29). Although an antiviral effect has been
281 described in rhinovirus-induced exacerbations, these results are highly controversial.
282 Peters et al (30) showed an association of ICS use and reduced expression of both ACE2
283 and TMPRSS2 receptors, thus implying that ICS may reduce the risk for SARS-CoV-2
284 infection and decrease COVID-19-related morbidity. Although our data cannot answer
285 this question in a conclusive manner, they show that the proportion of patients who used
286 ICS was significantly reduced in asthmatics who required hospitalization due to COVID-
287 19. These findings are consistent with other studies showing that a combination of
288 glycopyrronium, formoterol, and budesonide prevents the replication of HCoV-229E (via
289 inhibition of receptor expression and/or endosomal function), and that these drugs
290 modulate infection-related inflammation in the respiratory tract (31). In our study, the
291 three cortico-dependent patients in our study diagnosed with COVID-19 did not die from
292 it; however, there is no experimental evidence to date regarding the effect of systemic
293 corticosteroids in patients with asthma and COVID-19.

294 Whether treatment with biologics in patients with asthma impacts SARS-CoV-2
295 infection or the incidence and prognosis of COVID-19 also remains unknown. In this
296 context, there is no evidence supporting that either omalizumab or other drugs that
297 suppress eosinophils directly modulate viral processes in patients with asthma (32,33).
298 In our study, we identified a total of 865 patients treated with biologics. Among these,

299 two patients required admission and only one died from COVID-19; this patient, however,
300 had other comorbidities in addition to severe asthma, which may have contributed to his
301 poor clinical outcome. Overall, our results support the safety of these drugs for the
302 treatment of asthma in patients diagnosed with COVID-19. As with ICS use, our data
303 suggest that biologics might be associated with a protective effect on the clinical course
304 of these patients. However, we cannot rule out that the aforementioned favorable factors
305 also contributed to a better disease prognosis.

306 Our findings are consistent with a recently reported clinical series of 220
307 asthmatic patients with COVID-19 in Chicago and surrounding Illinois suburbs, where
308 asthma was not associated with an increased risk of hospitalization after adjusting for
309 age, sex, gender, and comorbidities (RR of 0.96 [95%CI: 0.77-1.19]) (34). However, ICS
310 use was associated with a non-statistically significant increased risk of hospitalization
311 (RR of 1.39 [95%CI: 0.90-2.15]); in the same report, however, the interpretation of the
312 effects of combined use of ICS and long-acting beta agonists (LABA) and levels of care
313 in these patients was not straightforward. These results warrant further research in
314 patients with asthma and other clinical populations.

315

316 **Strengths and Limitations**

317 The strengths of the present study include immediacy, large sample size, and real-world
318 evidence. In addition, our results must be interpreted in light of the following limitations.
319 First, the main limitation of this type of studies is perhaps the lack of documented
320 information. In Castilla-La Mancha, the digitalization of clinical records has been optimal
321 since 2011. Not only the EHRs system is homogenous throughout the region, but its use
322 has been universal for the past five years. Second, unlike classical research methods,
323 reproducibility is not generally considered in big data studies, since the latter involve
324 large amounts of information collected from the whole target population. Because we

325 exclusively analyzed the data captured in EHRs, the quality of the results reported for
326 some variables is directly tied to the quality of the clinical records; in many cases, EHRs
327 may be partially incomplete and not capture all the relevant clinical information from a
328 given patient. Third, because this study was not designed to collect variables in a strict,
329 *a priori* fashion, there were some variables that were not properly documented and were
330 therefore not analyzed. Finally, our study sample comprised COVID-19 cases confirmed
331 by both PCR/serological tests and clinical criteria (i.e. symptomatology, imaging, and
332 laboratory results). Of note, PCR and other rapid laboratory tests for the detection of
333 SARS-CoV-2 were not routinely used in Spain during the onset of the pandemic. The
334 decision to include clinically diagnosed COVID-19 cases is further supported by recent
335 data questioning the clinical validity and sensitivity of symptom- and image-based
336 identification of patients with COVID-19, especially in the early stages of the disease (35-
337 37).

338

339 **Conclusion**

340 We conclude that *a*) the frequency of SARS-CoV-2 infection has been low in patients
341 with asthma, although higher than in the general population, *b*) the increased risk for
342 hospitalization due to COVID-19 in patients with asthma is largely associated with age
343 and related comorbidities; mortality mainly affected elderly patients, *c*) ICS showed a
344 safe profile; compared to asthmatic patients who required hospitalization due to COVID-
345 19, a significantly higher percentage of non-hospitalized patients used ICS, and *d*)
346 although biologics-treated patients with asthma typically present with the most severe
347 manifestations of the disease, the number of COVID-19-related admissions and mortality
348 in these patients was strikingly low, thus suggesting a protective effect associated with
349 the use of these therapeutic agents.

350

351 **REFERENCES**

352

- 353 1. The Global Asthma Report 2014. Available at: [http://](http://www.globalasthmareport.org/burden/burden.php)
354 www.globalasthmareport.org/burden/burden.php
- 355 2. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable
356 health burden of chronic respiratory diseases, 1990-2017: a systematic analysis
357 for the Global Burden of Disease Study 2017. *Lancet Respir Med.* 2020 Jun; 8
358 (6):585-596. doi: 10.1016/S2213-2600(20)30105-3.
- 359 3. Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment. *J*
360 *Allergy Clin Immunol.* 2017; 139 (2): 438-447. doi: 10.1016/j.jaci.2016.06.054.
361 Epub 2016 Aug 20. Review.
- 362 4. Gibson GJ, Loddenkemper R, Lundbäck B, Sibille Y. Respiratory health and
363 disease in Europe: the new European Lung White Book. *Eur Respir J.* 2013; 42
364 (3):559–63.
- 365 5. Urrutia I, Aguirre U, Sunyer J, Plana E, Muniozguren N, Martínez-Moratalla J, et
366 al. Cambios en la prevalencia de asma en la población española del Estudio de
367 Salud Respiratoria de la Comunidad Europea (ECRHSII). *Arch Bronconeumol.*
368 2007; 43(8):425-30.
- 369 6. Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled
370 severe persistent asthma in pneumology and allergy hospital units in Spain. *J*
371 *Investig Allergol Clin Immunol* 2011; 21: 466–71.
- 372 7. Olaguibel JM, Quirce S, Juliá B, Fernández C, Fortuna AM, Molina J, et al.
373 Measurement of asthma control according to Global Initiative for Asthma
374 guidelines: a comparison with the Asthma Control Questionnaire. *Respir Res*
375 2012; 13:50. <https://doi.org/10.1186/1465-9921-13-50>.
- 376 8. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. *The Lancet* 2018; 391:
377 783–800. [https://doi.org/10.1016/S0140-6736\(17\)33311-1](https://doi.org/10.1016/S0140-6736(17)33311-1)
- 378 9. World Health Organization. Coronavirus disease (COVID-19) outbreak
379 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen)
380 [they-happen](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen).
- 381 10. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission
382 Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New*
383 *England Journal of Medicine.* 2020 Mar 26;382(13):1199-1207. doi:
384 10.1056/NEJMoa2001316.


- 385 11. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention,
386 diagnosis, treatment. *Crit Care*. 2019 Jun 12;23(1):214. doi: 10.1186/s13054-
387 019-2491-9.
- 388 12. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical
389 Characteristics of Covid-19 in New York City. *N Engl J Med* 2020.
390 <https://doi.org/10.1056/NEJMc2010419>.
- 391 13. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and
392 mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020.
393 <https://doi.org/10.1016/j.jaci.2020.04.006>.
- 394 14. Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe
395 outcomes? *Allergy* 2020. <https://doi.org/10.1111/all.14348>.
- 396 15. Mallappallil M, Sabu J, Gruessner A, Salifu M. A review of big data and medical
397 research. *SAGE Open Med*. 2020 Jun 25; 8: 2050312120934839. doi:
398 10.1177/2050312120934839. eCollection 2020
- 399 16. Hernandez Medrano ITG, J; Belda, C; Urena, A; Salcedo, I; Espinosa-Anke, L;
400 Saggion, H. SAVANA: Re-using Electronic Health Records with Artificial
401 Intelligence. *International Journal of Interactive Multimedia and Artificial*
402 *Intelligence*. 2017; 4 (7):8-12.
- 403 17. Espinosa-Anke LT, Pardo A, Medrano I, Ureña A, Salcedo I, Saggion H.
404 SAVANA: A Global Information Extraction and Terminology Expansion
405 Framework in the Medical Domain Procesamiento del Lenguaje Natural.
406 2016; 57: 23-30.
- 407 18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP;
408 STROBE Initiative. The Strengthening the Reporting of Observational Studies in
409 Epidemiology (STROBE) statement: guidelines for reporting observational
410 studies. *Lancet* 2007; 370: 1453-1457.
- 411 19. Benson T. Principles of Health Interoperability HL7 and SNOMED. London:
412 Springer. 201.
- 413 20. Baeza-Yates RA, Ribeiro-Neto B. 1999. Modern Information Retrieval. Addison-
414 Wesley Longman Publishing Co., Inc., Boston, MA, USA.
- 415 21. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical
416 characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
417 *Allergy* 2020. <https://doi.org/10.1111/all.14238>.
- 418 22. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic.
419 *Clin Rev Allergy Immunol* 2020. <https://doi.org/10.1007/s12016-020-08797-3>.

- 420 23. Gupta A, Bush A, Nagakumar P. Asthma in children during the COVID-19
421 pandemic: lessons from lockdown and future directions for management. *Lancet*
422 *Respir Med* 2020. Published Online June 25, 2020.
423 [https://doi.org/10.1016/S2213-2600\(20\)30278-2](https://doi.org/10.1016/S2213-2600(20)30278-2)
- 424 24. Almonacid Sánchez C, Melero Moreno C, Quirce Gancedo S, Sánchez-Herrero
425 MG, Álvarez Gutiérrez FJ, Bañas Conejero D, et al. PAGE Study: Summary of a
426 study protocol to estimate the prevalence of severe asthma in Spain using big-
427 data methods. *J Investig Allergol Clin Immunol* 2020:0.
428 <https://doi.org/10.18176/jiaci.0483>.
- 429 25. Izquierdo JL, Morena D, Gonzalez Y, Paredero JM, Perez B, Graziani D,
430 Gutierrez M, Rodriguez JM. Clinical Management of COPD in a Real-World
431 Setting. A Big Data Analysis. *Arch Bronconeumol* 2020. 2020 Feb 22; S0300-
432 2896(20)30012-0. doi: 10.1016/j.arbres.2019.12.025. Online ahead of print
- 433 26. Guan W-J, Liang W-H, Zhao Y, et al on behalf of China Medical Treatment Expert
434 Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-
435 19 in China: a nationwide analysis. *Eur Respir J*. 2020; In press. doi:
436 <https://doi.org/10.1183/13993003.00547-2020>.
- 437 27. Wang R, Bikov A, Fowler SJ. *Thorax* Epub ahead of print. doi:10.1136/thoraxjnl-
438 2020-2151189.
- 439 28. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a
440 systematic review and clinical perspective. *Eur Respir J* 2020;55.
441 <https://doi.org/10.1183/13993003.01009-2020>
- 442 29. Grünberg K, Sharon RF, Sont JK, et al. Rhinovirus-Induced airway inflammation
443 in asthma: effect of treatment with inhaled corticosteroids before and during
444 experimental infection. *Am J Respir Crit Care Med* 2001; 164: 1816–22.
- 445 30. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al;
446 National Heart, Lung, and Blood Institute Severe Asthma Research Program-3
447 Investigators. COVID-19 Related Genes in Sputum Cells in Asthma: Relationship
448 to Demographic Features and Corticosteroids. *Am J Respir Crit Care Med*. 2020
449 Apr 29. doi: 10.1164/rccm.202003-0821OC. Online ahead of print.
- 450 31. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al.
451 Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus
452 HCoV-229E replication and cytokine production by primary cultures of human
453 nasal and tracheal epithelial cells. *Respir Investig*. 2020 May;58(3):155-168. doi:
454 10.1016/j.resinv.2019.12.005. Epub 2020 Feb 21.

- 455 32. Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on rhinovirus
456 infections, illnesses, and exacerbations of asthma. *Am J Respir Crit Care Med*
457 2017; 196: 985–92
- 458 33. Sabogal Piñeros YS, Bal SM, van de Pol MA, et al. Anti-IL-5 in mild asthma alters
459 rhinovirus-induced macrophage, B-cell, and neutrophil responses (material). A
460 placebo-controlled, double-blind study. *Am J Respir Crit Care Med* 2019; 199:
461 508–17.
- 462 34. Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma
463 in hospitalized and non-hospitalized patients with COVID-19 [published online
464 ahead of print, 2020 Jun 15]. *J Allergy Clin Immunol*. 2020; S0091-
465 6749(20)30840-X. doi: 10.1016/j.jaci.2020.06.010
- 466 35. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H.
467 Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? *Eur J Radiol*
468 2020; 126: 108961.
- 469 36. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in
470 Different Types of Clinical Specimens. *JAMA* 2020.
- 471 37. T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation
472 of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in
473 China: A Report of 1014 Cases. *Radiology*: 0(0): 200642.

474 **FIGURES**

475



476

477 **FIGURE 1. Patient Flowchart.** Flowchart depicting the total number (%) of patients with
478 available EHRs, the number of patients with asthma, the number of patients diagnosed
479 with COVID-19, and of those, the number of hospitalizations after diagnosis during the
480 study period (January 1st, 2020-May 10th, 2020). All percent values are computed in
481 relation to the immediately above level.

482 **TABLES**

483 **Table 1. Demographic and clinical characteristics of patients with asthma with/without**
 484 **COVID-19**
 485

	Asthma (n=71,192)	Asthma without COVID-19 (n=70,544)	Asthma with COVID-19 (n=1,006)	OR (95% CI) <i>P</i> value *
<i>Age</i>				
Years (mean ± SD)	42 ± 24	41 ± 24	55 ± 20	< .001
<i>Sex</i>				
Female (%)	59	58	66	1.35 (1.18 – 1.54) <.001
<i>Tobacco use (%)</i>	10	9	11	1.25 (1.03 -1.53) 0.02
<i>Comorbidities</i>				
Arterial Hypertension (%)	24	23	39	2.02 (1.78 - 2.30) <.001
Dyslipidemia (%)	17	16	26	1.85 (1.60 – 2.13) <.001
Diabetes Mellitus (%)	11	11	16	1.54 (1.30 – 1.82) <.001
Obesity (%)	10	9	13	1.35 (1.12-1.62) <.001
Rhinitis (%)	33	33	17	0.42 (0.35 -0.49) <.001
Eczema (%)	7	7	1	0.50 (0.40 – 0.76) <.001

* Patients with asthma with COVID-19 vs. patients with asthma without COVID-19

486

487 **Table 2. Demographic and clinical characteristics of patients with asthma and COVID-19**
 488 **that required a hospital admission.**

489

	Asthma + COVID-19 (n=1,006)	Asthma + COVID-19 Non-Hospitalized (n=743)	Asthma + COVID-19 Hospitalized (n=263)	OR (95% CI) P value *
<i>Age</i>				
Years (mean ± SD)	55 ± 20	52 ± 20	63 ± 18	<.001
<i>Sex</i>				
Female (%)	66	67	61	0.76 (0.57 – 1.02) 0.07
<i>Tobacco use (%)</i>	7	7	6	0.69 (0.37 – 1.29) 0.29
<i>Comorbidities</i>				
Arterial Hypertension (%)	39	34	54	2.27 (1.71 – 3.03) <.001
Dyslipidemia (%)	27	21	38	2.31 (1.70 – 3.13) <.001
Diabetes Mellitus (%)	15	13	21	1.76 (1.22 – 2.54) 0.002
Obesity (%)	13	12	18	1.60 (1.09 – 2.35) 0.02

* Non-hospitalized patients vs. hospitalized patients

490

491 **Table 3. Treatment of patients with asthma and COVID-19: ICS and biologics in hospitalized**
 492 **vs. non-hospitalized patients.**

	Asthma + COVID-19 (Jan. 1 st - May 10 th , 2020)	Asthma + COVID-19 Hospitalized (Jan 1 st -May 10 th , 2020)	P value
<i>Patients with asthma</i> (N = 71.192) (Jan 1 st , 2019 – May 10 th , 2020)	1.006	263	
<i>Asthma + ≥ 1 ICS</i> (N = 42.171; 59,23% of asthmatics)	619	127	<.001
<i>Asthma + ≥ 1 Biologics</i> (N = 865; 1,21% of asthmatics) *	18	2	
Omalizumab (n=641)	9	0	
Mepolizumab (n=308)	7	2	
Benralizumab (n=98)	2	0	
Reslizumab (n=26)	1	0	

* 54% of the patients treated with Mepolizumab had been previously treated with Omalizumab; 65% of patients treated with Benralizumab had previously been treated with Omalizumab and 35% with Mepolizumab. Most of the patients treated with Reslizumab had been previously treated with Omalizumab and Mepolizumab.

493

494 **Table 4. In-hospital mortality in asthmatic patients with / without COVID-19**
495

	Asthma with COVID-19	Asthma without COVID-19	OR (95% CI) <i>P</i> value
<i>Age</i>			
Years (mean ± SD)	78 ± 17	76 ± 17	<.001
<i>Sex</i>			
Female (%)	61	71	0.64 (0.56 – 0.73)
<i>Mortality (%)</i>	2.29	0.54	2.29 (4.35 – 6.66)

496

497

498 **ONLINE APPENDIX**

499

500 **eTable 1. Search terms used to identify patients with bronchial asthma**

- Unstable asthma
- Adult-onset asthma
- Intrinsic asthma
- Asthma attack / Asthma exacerbation
- Acute asthma
- Exercise-induced asthma
- Childhood asthma
- Asthmatic bronchitis
- Cough-variant asthma
- Allergic asthma
- Mild asthma
- Moderate asthma
- Occasional asthma
- Severe asthma
- Chemical-induced asthma
- Substance-induced asthma
- Intermittent asthma
- Seasonal Asthma
- Occupational Asthma
- Chronic obstructive airway disease with asthma
- Asthma with irreversible airway obstruction
- Untreated Asthma
- Persistent asthma
- Induced asthma
- Neutrophilic asthma
- Cortico-dependent asthma

501